Skip to main content

Table 3 Associations between KLK5 status and the clinicopathological variables of the breast cancer patients

From: Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions

   No. of patients (%)  
Variable Total KLK5 - negative KLK5 - positive p value
Menopausal status*     
Pre/peri 54 22 (40.7) 32 (59.3) 0.005b
Post 47 33 (70.2) 14 (29.8)  
Gradec     
I 3 1 (33.3) 2 (66.7)  
II 30 21 (70.0) 9 (30.0) 0.34d
III 34 25 (73.5) 9 (26.5)  
TNM Tumor size     
<2 cm 26 17 (65.4) 9 (34.6)  
2-5 cm 37 27 (73.0) 10 (27.0) 0.79d
> 5 cm 4 3 (75.0) 1 (25.0)  
ER status     
Negative 16 7 (43.8) 9 (56.3) 0.028b
Positive 51 39 (76.5) 12 (23.5)  
PR status     
Negative 24 15 (62.5) 9 (37.5) 0.42b
Positive 43 31 (72.1) 12 (27.9)  
  1. a Cutoff point: 820 c/Kc equal to 70th percentile
  2. b Fisher's Exact Test
  3. c Bloom-Scarff-Richardson grading system
  4. d χ2 test
  5. cTNM system
  6. * In the total studied population